# NEXICART-2 (NCT06097832)

> Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06097832
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Nexcella Inc.
- Conditions: Light Chain (AL) Amyloidosis
- Interventions: NXC-201 CAR-T
- Enrollment: 45
- Primary outcome: Number of Participants With Treatment-Related Adverse Events
- Primary outcome: Number of Participants with Adverse Events by Severity as Assessed by CTCAE v5.0
- Primary outcome: To confirm the maximum tolerated dose (MTD)
- Primary outcome: To confirm the recommended phase 2 dose (RP2D)

## Commentary we found

- X threads: 9
- YouTube: 4
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nexicart-2-nct06097832

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06097832", "email": "<work email>"}; the inbox owner confirms by the emailed link.